Jing Yan's research while affiliated with Shanghai University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (5)
Lipid nanovehicles are currently the most advanced vehicles used for RNA delivery, as demonstrated by the approval of patisiran for amyloidosis therapy in 2018. To illuminate the unique superiority of lipid nanovehicles in RNA delivery, in this review, we first introduce various RNA therapeutics, describe systemic delivery barriers, and explain the...
Currently, biological membrane-derived nanoparticles (NPs) have shown enormous potential as drug delivery vehicles due to their outstanding biomimetic properties. To make these NPs more adaptive to complex biological systems, some methods have been developed to modify biomembranes and endow them with more functions while preserving their inherent n...
Acid oligopeptide-modified liposomes show promising bone-targeting activity. However, as the modification density of acid oligopeptides increases, liposomes may exhibit stronger hydroxyapatite (HA)-binding activity and decreased blood pharmacokinetics (PK), exerting opposite effects on their bone-targeted delivery. Nowadays, little research has sys...
Citations
... In this approach, rhPON1 is genetically fused with other proteins/peptides to increase its overall size or charge, and the fused protein exhibits improved pharmacokinetic properties [77,75,100] 3. Site targeting 1.Blood-brain barrier permeability: rhPON1 fusion with certain proteins increases its blood-brain barrier permeability [74,99] A study involving IIG1 PON1 mutant in guinea pigs and another one conducted on mice expressing 1-I-F11 PON1 mutant through an adenovirus expression system have shown that they are able to afford protection (>80%) against G-agents [68,78]. Furthermore, Meek et al. reported that pyridinium oximes-based nucleophiles acting as PON1 nerve agents hydrolysis activity enhancers reduced brain and peripheral AChE inhibition by sarin and VX surrogates in Sprague-Dawley rats [79]. ...
... • Less immunogenic • Simple manufacturing process • Characteristic are very dependent upon pH adjustments. • Lack of large-scale and reproducible production [31] • Rapidly eliminated from the circulatory system • Affected stability by their hollow structure [140,141] 2. ...
... Nanotechnology has various medical applications such as diagnosis [1][2][3], therapy [4,5], and theranostics [6,7], and nanoparticle-based therapy is currently advancing. In recent years, extracellular vesicles (EVs) have attracted significant attention [8][9][10]. ...
... ERMs@siM13 was prepared using a thin-film hydration method, as previously reported [34,35] C6 = x:100-x:8:0.5, mol: mol; x = 5, 10, and 15) following the abovementioned procedure. ...
